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Abstract
Introduction Methadone, the most widely delivered
maintenance therapy for heroin addicts, may be responsible for
life-threatening poisonings with respiratory depression. The
toxicokinetics and the toxicokinetic/toxicodynamic (TK/TD)
relationships of methadone enantiomers have been poorly
investigated in acute poisonings. The aim of this study was to
describe the relationships between methadone-related
respiratory effects and their corresponding concentrations.
Methods We report a 44-year-old methadone-maintained
patient who ingested a 240-mg dose of methadone. He was
found comatose with pinpoint pupils and respiratory depression.
He was successfully treated with intravenous naloxone infusion
over the course of 31 hours at a rate adapted to maintain normal
consciousness and respiratory rate. We performed a TK/TD
analysis of the naloxone infusion rate needed to maintain his
respiratory rate at more than 12 breaths per minute (as
toxicodynamics parameter) versus plasma R,S- and R-
methadone concentrations (as toxicokinetics parameter),
determined using an enantioselective high-performance liquid
chromatography assay.
Results Initial plasma R,S-methadone concentration was 1,204
ng/ml. Decrease in plasma R- and S-methadone concentrations
was linear and demonstrated a first-order pharmacokinetics
(maximal observed concentrations 566 and 637 ng/ml, half-lives
16.1 and 13.2 hours, respectively). TK/TD correlation between
naloxone infusion rate and R,S- and R-methadone
concentrations fitted well a sigmoidal Emax model (concentration
associated with a half-maximum effect [EC50] 334 and 173 ng/
ml, Hill coefficient 10.0 and 7.8, respectively). In our chronically
treated patient, EC50 values were in the range of previously
reported values regarding methadone analgesic effects,
suggesting that plasma methadone concentrations to prevent
withdrawal are lower than those associated with methadone
analgesic effects.
Conclusion After the ingestion of a toxic dose of a racemic
mixture, plasma R- and S-enantiomer concentrations decreased
in parallel. Despite large inter-individual variability in methadone
toxicokinetics and toxicodynamics, TK/TD relationships would
be helpful for providing quantitative data regarding the
respiratory response to methadone in poisonings. However,
further confirmatory TK/TD data are needed.
Introduction
Methadone has been the most widely delivered maintenance
therapy for heroin users for almost 50 years. Prescribed with
doses adequate to the actual needs of individual addicts,
methadone efficiently reduces heroin use, overdose mortality,
as well as criminal activities [1-3]. The major pharmacological
activity of methadone, a long-lasting opioid agonist, is related
to its binding to the mu-opioid receptors. The available mar-
keted methadone (6-dimethylamino-4,4-diphenyl-3-hep-
tanone) is a racemic mixture of two stereoisomeric forms, the
R- and S-enantiomers [4]. R-methadone is the main pharma-
cologically active isomer, believed to account for most if not allPage 1 of 7
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ment. However, although lacking strong opioid effects, S-
methadone may play a significant role in the adverse
responses to R,S-methadone [5-7].
Opioid toxicity produces a classic syndrome characterised by
a depressed level of consciousness, bradypnea, and miosis.
Methadone overdose results in life-threatening respiratory
depression, which may be reversed using naloxone, a mu-
receptor competitive antagonist [8]. Regardless of whether
initial doses of naloxone restore adequate respiration and fur-
ther therapy is needed, repeated boluses or continuous infu-
sion of naloxone can be used [9,10]. In the setting of close
monitoring of neurological and respiratory parameters,
naloxone may obviate the need for tracheal intubation and
mechanical ventilation.
To our knowledge, toxicokinetic/toxicodynamic (TK/TD) rela-
tionships in regard to respiratory depression have not been
studied in methadone poisonings. Moreover, the relative kinet-
ics of each methadone enantiomer after the ingestion of a toxic
dose remains unclear. Here, we report a case of methadone
poisoning with severe respiratory depression treated using
naloxone. We performed a toxicokinetics study of both S- and
R-methadone enantiomers and a TK/TD study to understand
the relationships between the respiratory effects and the con-
centrations of the active R-enantiomer.
Materials and methods
A 44-year-old man was found unconscious outdoors and
admitted to the emergency department of a neighbouring hos-
pital. On presentation, he was comatose (Glasgow Coma
Score 3) with a blood pressure of 118/71 mm Hg, a heart rate
of 117 beats per minute, a respiratory rate of 10 breaths per
minute, and an SpO2 (percutaneous oxygen saturation) of
75%. His temperature was 36.5°C. Neurological examination
showed hypotonic and hyporeflexic coma with pinpoint pupils.
Pulmonary auscultation was normal. Arterial blood gas analy-
sis while breathing on room air showed a pH of 7.30, a PaO2
(arterial oxygen pressure) of 56 mm Hg, PaCO2 (arterial car-
bon dioxide pressure) of 48 mm Hg, and a serum bicarbonate
concentration of 26 mmol/l. Other routine laboratory tests
were unremarkable. Plasma lactate concentration was 2.1
mmol/l. Significant improvement in consciousness level (Glas-
gow Coma Score 15) without mental confusion was obtained
after an intravenous bolus injection of 0.3 mg of naloxone fol-
lowed by a continuous 0.3-mg/hour infusion. The patient rap-
idly awoke and declared that he had intentionally ingested 240
mg (3.14 mg/kg) of methadone and 2 mg of flunitrazepam to
relax. The delay between ingestion and admission to the hos-
pital was estimated to be 2.7 hours. He had a history of heroin
addiction with a maintenance treatment of 70 mg/day of meth-
adone (confirmed by a prescription from his maintenance pro-
gram centre) and occasional use of 2 mg of flunitrazepam. He
suffered from depression, and a recently diagnosed hyperthy-
roidism was treated with neomercazole. He was transferred for
monitoring to our intensive care unit (ICU). The attending phy-
sicians managed the patient according to the standard treat-
ment guidelines currently used in our department. Naloxone
infusion rate was progressively adapted, aiming to keep the
patient calm with a normal mental status (Glasgow Coma
Score 15) and a respiratory rate of more than 12 breaths per
minute. Reduction in naloxone dose was systematically
attempted, and when evidence of toxicity occurred, a return to
the previous dose was made. Routine toxicological screening
of blood and urine, including benzodiazepines, opiates,
buprenorphine, cocaine, and tetrahydrocannabinol, was nega-
tive, except for methadone. This case outcome was favourable
with an uneventful 48-hour ICU stay, except for an aspiration
pneumonia treated with amoxicillin-clavulanic acid for six days.
The duration of naloxone intravenous infusion was 31 hours
with a cumulative dose of 9.1 mg.
R-methadone accounts for most, if not all, of the effect of
methadone [5-7]. To this extent, we considered that TK/TD
relationships in regard to methadone respiratory effects for S-
enantiomer would probably just mirror those of R-enantiomer.
Therefore, we performed a TK/TD analysis of the naloxone
infusion rate needed to maintain the respiratory rate of more
than 12 breaths per minute (as toxicodynamics parameter)
versus plasma R,S- and R-methadone concentrations (as tox-
icokinetics parameter). Upon admission to the ICU, verbal
informed consent was obtained from the completely awak-
ened and non-confused patient. Venous blood samples were
obtained at 2.7, 10.5, 14.5, 18.5, 20.5, 22.5, 26.5, and 30.5
hours after methadone ingestion. Plasma was separated and
frozen until methadone concentration measurement. The rate
of naloxone infusion was prospectively collected at each blood
sampling time, and the nurses in charge were blinded to the
results of the toxicological analyses. Both R- and S-metha-
done enantiomer concentrations were measured using a vali-
dated chiral high-performance liquid chromatography assay as
previously described [11]. The plasma kinetics of each enanti-
omer were analysed using a noncompartmental method. Toxi-
cokinetics parameters and TK/TD relationships were
determined using a computerised curve-fitting program (Win-
Nonlin Pro 3.0; Pharsight Corporation, Mountain View, CA,
USA). The area under the curve from 0 to infinity (AUCinf) was
calculated using the model-independent trapezoidal method.
Results
The maximal observed plasma concentration of R,S-metha-
done was 1,204 ng/ml at 2.7 hours (Table 1). Decrease in
plasma R,S-, R-, and S-methadone concentrations was of first-
order pharmacokinetics (Figure 1). During the course of over-
dose after naloxone infusion, the respiratory rate was main-
tained at more than 12 breaths per minute (therapeutic
objective). The Glasgow Coma Score was constantly at 15,
and the haemodynamic parameters were within the normal
range. TK/TD correlations between naloxone infusion rate (E)Page 2 of 7
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sigmoidal Emax model, E = EmaxCγ/[EC50γ + Cγ] + E0, where E0
is the baseline value of the measured rate of naloxone infusion,
Emax represents the maximum possible infusion rate, EC50 rep-
resents the concentration associated with the half-maximum
infusion rate, and γ (or Hill coefficient) determines the steep-
ness (slope) of the concentration-versus-response curve (Fig-
ure 2). Values of EC50 and γ are given in Table .
Discussion
Methadone pharmacokinetics and pharmacodynamics are
characterised by a high inter-individual variability, even in toxic
conditions [7,12,13]. There is up to 17-fold inter-individual var-
iation of blood methadone concentrations for a given dosage
[7]. Because methadone is administered as a racemic mixture,
our objective was to study the relationships between the res-
piratory effects and the racemic as well as the active R-enan-
tiomer concentrations.
R-methadone is believed to account for most, if not all, of the
therapeutic effects of methadone maintenance treatment [5-
7,14]. S-methadone may be a clinically important determinant
of adverse responses to racemic methadone and may
significantly contribute to the adverse but not the therapeutic
effects of racemic methadone during maintenance treatment
for opioid dependence. In healthy volunteers, 7.5 mg of oral S-
methadone did not significantly differ from the placebo
response in respiratory and pupillary effects, whereas 7.5 mg
of R-methadone and 15 mg of R,S-methadone induced dra-
matic and sustained respiratory depression and miosis [15]. In
the same volunteers, S-methadone doses between 50 and
100 mg slightly depressed ventilation. In dependent patients,
S-methadone administered at dosages of 650 to 1,000 mg/
day induced subjective morphine-like effects, partially sup-
pressed abstinence from morphine, and created a mild degree
of physical dependence [16].
At therapeutic doses, plasma concentrations of R,S-metha-
done decrease in a bi-exponential manner, with an elimination
half-life estimated at 22 ± 7 hours (range 14 to 40) in opioid
users after 26 days of methadone [7]. Trough plasma concen-
trations of 400 ng/ml for R,S-methadone or 250 ng/ml for R-
methadone are usual target values when measurement of
methadone concentration is performed to investigate a non-
complete clinical response [17]. In our overdosed patient, the
maximal observed R,S-methadone concentration was approx-
imately three times higher than the reported peak levels in
patients treated with a daily therapeutic dosage of more than
80 mg [18].
The almost mono-exponential first-order decline in plasma R-
and S-methadone concentrations suggests the absence of
any saturation of the distribution and the elimination proc-
esses, even at supra-therapeutic concentrations. Methadone
toxicokinetics was in close agreement with pharmacokinetics,
with an observed half-life in the lower range of the reported
pharmacokinetic half-lives [7]. Methadone is metabolised
mainly into EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyr-
rolidine) through cytochrome P450 (CYP) 3A4 and 2B6 path-
ways, for which genetic polymorphisms and high inter-
individual variability of activity were reported, resulting in large
inter-individual variability of methadone half-lives. In vitro
metabolism studies using human liver microsomes showed
apparent affinity constants (Km) regarding CYP-mediated
EDDP formation far above the maximal observed methadone
concentration in this patient [19], suggesting that saturation of
methadone metabolism did not occur in our patient. Moreover,
no study of methadone dose-linearity was performed at such
elevated concentrations. Thus, we may hypothesise that simi-
lar data (first-order kinetics) would have been observed with a
larger data set of intoxicated patients presenting similar
plasma methadone concentrations. Both enantiomer half-lives
were rather short in comparison to previously reported values
in eight patients undergoing methadone maintenance treat-
ment (R-methadone 23 to 50 hours and S-methadone 16 to
37 hours) [20]. Thus, although no definitive explanation could
be given, we may suggest that our patient was an extensive
CYP 3A4 metaboliser, because no CYP 3A-inducing drugs
were identified in his treatment. Moreover, as previously
reported [7], the half-life of R-methadone was longer than that
of S-methadone.
TK/TD relationships allow the descriptive and quantitative
characterisation of the time course of the in vivo drug effect in
relation to its corresponding drug concentrations within an
individual [21]. There are several studies dealing with pharma-
cokinetic/pharmacodynamic relationships for opioids com-
monly used in anaesthesia or for the treatment of pain [22,23].
Table 1
Toxicokinetic parameters of the racemic R,S-methadone and both R- and S-methadone forms in a severely poisoned patient
T1/2 Maximal observed concentration AUCinf Vz/F Clt/F
(h) (ng/ml) (ng-h/ml) (l) (l/h)
R-methadone 16.1 566 13,241 211 9.1
S-methadone 13.2 637 13,385 170 9.0
R,S-methadone 14.5 1,204 26,508 189 9.1
AUCinf, area under the curve from 0 to infinity; Clt/F, total plasma clearance; T1/2, half-life; Vz/F, distribution volume.Page 3 of 7
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macokinetic/pharmacodynamic relationships of methadone in
healthy volunteers, patients treated for chronic pain, or mainte-
nance patients [5,23-25]. To our knowledge, there is no case
of human methadone poisoning with a TK/TD analysis of res-
piratory effects. In our patient, we found sigmoidal TK/TD rela-
tionships. The maximal naloxone infusion rate was associated
with an R, S-methadone concentration ranging from 400 to
1,200 ng/ml, suggesting a saturation of the mu-opioid recep-
tors at these concentrations. Similarly, a study in healthy volun-
teers showed a sigmoidal response with minimal hysteresis
between the iris/pupil ratio and its corresponding plasma R-
methadone concentration (EC50 2.3 ng/ml and γ 9.0) [5]. In
patients with chronic pain, pain relief was related to the R, S-
methadone concentrations by a sigmoid Emax model defined
with an EC50 of 290 ng/ml and a steepness of 2.03 [25]. In our
case, the high value of γ (10.0) clearly indicated that a small
decrease in plasma concentrations near the EC50 was associ-
ated with a dramatic decrease in the rate of naloxone infusion.
R-methadone exhibited a lower γ than R,S-methadone, sug-
gesting that S-methadone enantiomer could demonstrate a
positive allosteric cooperation with R-methadone activity.
However, in the present case, the confidence intervals
regarding the γ values were largely overlapping, precluding
any definitive conclusion. R,S-methadone EC50 of 334 ng/ml
was associated with significant respiratory effects in our
patient. This concentration was less elevated than the target
concentration of 400 ng/ml in patients treated with elevated
doses, suggesting that our patient was probably equilibrated
with lower methadone concentrations. However, a relationship
if any between EC50 and a therapeutic drug monitoring tool, as
the trough plasma R,S-methadone concentration need to be
established.
Moreover, although we may hypothesise that the EC50 values
regarding methadone respiratory effects in our patient are
higher than values that could have been observed in opiate-
naïve patients due to a pharmacodynamic tolerance, these
EC50 values were in the same range as those obtained for pain
relief in chronically treated patients [25]. Increase of EC50
could also be related in our patient to a pharmacogenetic var-
iant of mu-receptor, as previously reported [26]. Thus, our data
clearly support the tight safety index of methadone, previously
illustrated by the occurrence of significant respiratory effects
after intake at pharmacological dosages [27]. Consistently,
during the first months of methadone maintenance, there is a
continual alveolar hypoventilation due to the depression of
both central and peripheral chemoreception [28]. Interest-
ingly, alteration in ventilatory response to hypoxia persists after
a prolonged treatment, although alveolar hypoventilation is
abolished after the fully acquired tolerance within two months
of the carbon dioxide-sensitive chemoreflex. However, this
adaptation of ventilatory response to chronic use of metha-
done does not prevent the occurrence of alveolar hypoventila-
tion in the case of acute methadone overdose.
Our toxicokinetics study has significant limitations. First,
AUCinf could be slightly underestimated due to the absence of
any sample before 2.7 hours post-ingestion and between 2.7
and 10.5 hours, as the mean maximal observed concentration
has been previously reported between 2.5 and 4.4 hours post-
ingestion [29]. The bioavailability of methadone is also
unknown in such an overdose situation. In addition, the AUC
versus time was calculated between 0 and infinity as if our
Figure 1
Plasma R,S-, R-, and S-methadone concentrations (left y-axis) and naloxone infusion rate (righ  y-axis) versus time after ingestion of a 3.14-mg/kg single oral dose of the racemic R,S- thadone
naloxone infusion rate (right y-axis) versus time after ingestion of a 3.14-
mg/kg single oral dose of the racemic R,S-methadone.
Figure 2
Toxicokinetic/toxicodynamic relationships between the naloxone infu-si n rate and he plasm  concentrations of (a) the racemic R,S-metha-d e nd (b) R-methadon  en ntiomer
sion rate and the plasma concentrations of (a) the racemic R,S-metha-
done and (b) the R-methadone enantiomer.Page 4 of 7
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possible long-term maintenance therapy, which was not cer-
tain in the absence of previous therapeutic drug monitoring.
Thus, the apparent volume of distribution (Vz/F) and the total
plasma clearance (Clt/F) values calculated using AUCinf
should be interpreted with caution. However, Clt/F and Vz/F
values for both methadone enantiomers were comparable to
those reported in patients undergoing methadone mainte-
nance at therapeutic dosage [20], suggesting the absence of
saturation of methadone pharmacokinetics in this case. The
Vz/F values of R- and S-methadone (211 versus 170 l, respec-
tively) were lower than those reported in treated patients (470
versus 318 l, respectively [20]) but similar to those reported in
healthy volunteers (106 versus 262 l, respectively [7]). We
have no definitive explanations for these differences, due to
the imprecision of the AUCinf calculation. However, metha-
done Vz/F is influenced by the acid α-1-glycoprotein levels
with regard to its transfer to and from the central to the periph-
eral compartments and by extension to the site of methadone
pharmacological action [7]. The Clt/F was similar for both
methadone R- and S-enantiomers (9.0 versus 9.1 l/hour,
respectively) and close to values reported in treated patients
(10.7 versus 9.7 l/hour, respectively [20]). In contrast, in
healthy adults, the pharmacologically active R-enantiomer has
a lower Clt/F when compared with S-methadone (4.0 versus
20.4 l/hour, respectively) [7].
We considered the naloxone infusion rate as a surrogate
marker of methadone-induced respiratory depression. How-
ever, because the elimination rate of naloxone varies with a
half-life of 45 to 90 minutes, a continuous infusion runs the risk
of naloxone accumulation, complicating the pharmacodynamic
interactions. Otherwise, such a toxicodynamics surrogate
marker requires a close concordance between real effects on
respiration and the titrated infusion rate of naloxone. Moreover,
serum and urine specimens were not tested for flunitrazepam
in our patient. Consistently, one unusual feature in this case is
the rapidity with which the patient appears to have suffered
unconsciousness. Given that the peak effects of methadone
usually occur approximately four to six hours after ingestion [7]
and that flunitrazepam is a short-acting agent with respect to
methadone, we think the initial presentation may have been
influenced by the co-ingestion of flunitrazepam. However, sev-
eral studies suggest that methadone peak plasma concentra-
tions and effects may occur much earlier [30,31], supporting
(as in our patient) methadone-related steep concentration-
effect relationships. Otherwise, we cannot rule out potential
interactions between flunitrazepam and methadone that con-
tributed to the respiratory depression. Both molecules are
metabolised by the CYP 3A4, which may lead to clinically sig-
nificant drug-drug interactions. However, the relatively short
half-life of R, S-methadone does not support any inhibition of
CYP 3A4-mediated methadone metabolism by flunitrazepam.
Sources of inter-individual variability of the response to meth-
adone are numerous, including demographic and physio-
pathological characteristics of the methadone-maintained
subjects [23,32]. Thus, analysis of the TK/TD relationships in
one patient precludes any definitive conclusion regarding the
various possible situations of exposures to methadone in other
patients. In addition, because plasma is not the effect site of
methadone and time is needed before the drug distributes into
the central nervous system, another significant concern in our
study is the absence of characterisation of the plasma-versus-
biophase distribution. For some opioids, there may be a delay
between the time course of the plasma concentrations and the
time course of the effects [5,22,25]. Moreover, the rate of
plasma protein binding was not determined in this patient.
However, because methadone is a highly lipophilic drug, the
rate of cerebral distribution of the pharmacologically active
molecules should not be a limiting step in this study of TK/TD
relationships at toxic concentrations. Here, we described TK/
TD relationships during the methadone elimination phase.
Conclusion
Plasma toxicokinetics of R- and S-methadone enantiomers
were parallel. The study of TK/TD relationships appears to be
helpful for quantifying the respiratory response to methadone
during poisonings. Despite a possible pharmacodynamic tol-
erance in our patient, the EC50 values regarding the metha-
done respiratory effects were in the same range as those
previously reported for the analgesic effects in chronically
treated patients, thus suggesting a limited safety index for
methadone. A better understanding of the toxicokinetics and
toxicodynamics of methadone and its enantiomers will be pos-
sible as more data accumulate in this regard.
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Key messages
• Methadone may be responsible for life-threatening poi-
sonings with respiratory depression.
• The pharmacokinetics of plasma R- and S-methadone 
enantiomers is of first order, with elimination half-lives of 
16.1 and 13.2 hours, respectively.
• The TK/TD correlation between the naloxone infusion 
rate needed to maintain a respiratory rate of more than 
12 breaths per minute and R,S- and R-methadone con-
centrations fits well a sigmoidal Emax model (EC50 334 
and 173 ng/ml, γ 10.0 and 7.8, respectively).
• Despite large inter-individual variability, TK/TD relation-
ships would be helpful for providing quantitative data on 
the respiratory response to methadone in poisonings.
• In the reported chronically treated patient, EC50 values 
are in the range of the previously described values for 
methadone analgesic effects.Page 6 of 7
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